Budesonide

Generic Name
Budesonide
Brand Names
Airsupra, Breyna, Breztri, Cortiment, Entocort, Pulmicort, Pulmicort Turbuhaler, Rhinocort, Symbicort, Tarpeyo, Uceris, Jorveza, Kinpeygo
Drug Type
Small Molecule
Chemical Formula
C25H34O6
CAS Number
51333-22-3
Unique Ingredient Identifier
Q3OKS62Q6X
Background

Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.

Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product with formoterol.

Indication

Budesonide extended release capsules are indicated for the treatment and maintenance of mild to moderate Crohn’s disease. Various inhaled budesonide products are indicated for prophylactic therapy in asthma and to reduce exacerbations of COPD. A budesonide nasal spray is available over the counter for symptoms of hay fever and upper respiratory allergies. E...

Associated Conditions
Allergic Reaction, Allergic Rhinitis (AR), Asthma, Bronchoconstriction, Chronic Obstructive Pulmonary Disease (COPD), Collagenous Colitis, Crohn's Disease (CD), Eosinophilic Esophagitis, Exacerbation of asthma, Nasal Congestion, Nasal Polyps, Proteinuria, Pruritus, Rhino Sinusitis, Ulcerative Colitis, Vasomotor Rhinitis, Corticosteroid-responsive dermatoses, Mild Crohn’s Disease, Moderate Crohn’s Disease
Associated Therapies
Maintenance therapy
Clinical Trials
Related News

Study to Evaluate Efficacy and Safety of Pulmicort Respules in Japanese Adult Asthmatic Patients

Phase 3
Completed
Conditions
Asthma
Interventions
Drug: Budesonide
Drug: Pulmicort Turbuhaler
First Posted Date
2009-03-05
Last Posted Date
2011-03-11
Lead Sponsor
AstraZeneca
Target Recruit Count
108
Registration Number
NCT00855959
Locations
🇯🇵

Research Site, Tachikawa, Tokyo, Japan

🇯🇵

Research City, Hino, Tokyo, Japan

Budesonide 3x3mg/d Versus Prednisone in Active Autoimmune Hepatitis

Phase 2
Completed
Conditions
Autoimmune Hepatitis
Interventions
Drug: budesonide
Drug: prednisone
First Posted Date
2009-02-06
Last Posted Date
2019-05-07
Lead Sponsor
Dr. Falk Pharma GmbH
Target Recruit Count
208
Registration Number
NCT00838214
Locations
🇩🇪

Medical School Hannover, Hannover, Niedersachsen, Germany

Budesonide Foam Versus Placebo for Prevention of Acute Radiation Proctitis

Phase 2
Terminated
Conditions
Radiation Proctitis
Interventions
Drug: budesonide
Drug: Placebo foam
First Posted Date
2009-01-23
Last Posted Date
2012-01-30
Lead Sponsor
Dr. Falk Pharma GmbH
Target Recruit Count
17
Registration Number
NCT00828230
Locations
🇩🇪

Klinik für Radioonkologie und Strahlentherapie - Klinikum Braunschweig, Braunschweig, Germany

🇩🇪

Strahlentherapie, St. Vincentius-Kliniken gAG, Karlsruhe, Germany

🇩🇪

Strahlentherapie, Klinikum Mutterhaus der Borromäerinnen, Trier, Germany

Innate Immune Responses in Chronic Obstructive Pulmonary Disease (COPD) Patients

Phase 3
Completed
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Drug: Budesonide
First Posted Date
2009-01-21
Last Posted Date
2013-09-11
Lead Sponsor
Mahidol University
Target Recruit Count
20
Registration Number
NCT00826163
Locations
🇹🇭

Kittipong Maneechotesuwan, Bangkoknoi, BKK, Thailand

Oral Treatment With PL-56 in Patients With IgA Nephropathy - an Explorative Study

Phase 2
Completed
Conditions
IGA Nephropathy
Interventions
Drug: Budesonide
First Posted Date
2008-10-07
Last Posted Date
2009-04-21
Lead Sponsor
Calliditas Therapeutics AB
Target Recruit Count
20
Registration Number
NCT00767221
Locations
🇸🇪

Linköping University Hospital, Linköping, Sweden

🇸🇪

Uppsala University Hospital, Uppsala, Sweden

🇸🇪

Huddinge University Hospital, Stockholm, Sweden

Dose-Ranging Study of Oral Viscous Budesonide in Pediatrics With Eosinophilic Esophagitis

First Posted Date
2008-09-30
Last Posted Date
2021-06-11
Lead Sponsor
Shire
Target Recruit Count
82
Registration Number
NCT00762073
Locations
🇺🇸

Stanford University Medical Center, Palo Alto, California, United States

🇺🇸

The Center for Human Nutrition, Omaha, Nebraska, United States

🇺🇸

Carilion Pediatric Gastroenterology, Roanoke, Virginia, United States

and more 17 locations

Ursodeoxycholic Acid Plus Budesonide Versus Ursodeoxycholic Acid Alone in Primary Biliary Cirrhosis (PBC)

First Posted Date
2008-09-04
Last Posted Date
2020-01-28
Lead Sponsor
Dr. Falk Pharma GmbH
Target Recruit Count
62
Registration Number
NCT00746486
Locations
🇩🇪

Universitätsklinikum Bonn, Bonn, NRW, Germany

🇫🇷

Hôpital Saint-Antoine, Paris, France

Budesonide Capsules Versus Mesalazine Granules in Active Ulcerative Colitis (UC)

Phase 3
Completed
Conditions
Colitis, Ulcerative
Interventions
Drug: budesonide
Drug: mesalazine
First Posted Date
2008-09-04
Last Posted Date
2012-06-26
Lead Sponsor
Dr. Falk Pharma GmbH
Target Recruit Count
343
Registration Number
NCT00747110
Locations
🇩🇪

Klinikum St. Marien, Amberg, Germany

The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis

First Posted Date
2008-08-05
Last Posted Date
2016-01-14
Lead Sponsor
Mayo Clinic
Target Recruit Count
51
Registration Number
NCT00728481
Locations
🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

The Effects of Different Long-acting Bronchodilator Medications on Asthma Patients With Different Genetic Variations

First Posted Date
2008-06-27
Last Posted Date
2017-05-31
Lead Sponsor
Brigham and Women's Hospital
Target Recruit Count
255
Registration Number
NCT00706446
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy